The brief

Analyst view

• ReWalk got the first FDA clearance for a spinal-cord-injury exoskeleton (2014); ReWalk 7, the 7th generation, was cleared in March 2025.
• Medicare set a $91,032 payment for personal exoskeletons from April 2024, the first real route for patients to afford one.
• Small and cash-constrained: Q2 2026 revenue was $6.6M (ReWalk plus AlterG); July 2026 notes raised $5.6M, with $5.6M more on milestones.

Technical approach

As reported

Powered joints

Motors at hips and knees

Gears and motors at each hip and knee move the legs through a walking pattern; the ankles and the user's crutches provide balance.

Intent

Body tilt starts each step

A tilt sensor reads when the user leans forward and shifts weight, and the exoskeleton takes the next step in response.

Real-world use

Built for home and street

Unlike clinic-only rehab frames, ReWalk is labelled for daily use at home and in the community, including stairs and curbs.